Hypertrophic Cardiomyopathy Market Set for Transformation Over the Next Decade with the Emergence of Targeted Cardiac Therapies Beyond Conventional Beta-blockers, Calcium Channel Blockers, and Antiarrhythmic Agents | DelveInsight

The hypertrophic cardiomyopathy market is expected to witness significant growth, driven by increasing disease awareness, improved diagnosis rates, and the emergence of targeted disease-modifying therapies including Sotagliflozin (ZYNQUISTA) (Lexicon Pharmaceuticals), Ninerafaxstat...